The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Next-generation personalised medicine for high-risk paediatric cancer patients – The INFORM pilot study
Open accessAbstract
The 'Individualized Therapy for Relapsed Malignancies in Childhood' (INFORM) precision medicine study is a nationwide German program for children with high-risk relapsed/refractory malignancies, which aims to identify therapeutic targets on an individualised basis. In a pilot phase, reported here, we developed the logistical and analytical pipelines necessary for rapid and comprehensive molecular profiling in a clinical setting. Fifty-seven patients from 20 centers were prospectively recruited. Malignancies investigated included sarcomas (n = 25), brain tumours (n = 23), and others (n = 9). Whole-exome, low-coverage whole-genome, and RNA sequencing were complemented with methylation and expression microarray analyses. Alterations were assessed for potential targetability according to a customised prioritisation algorithm and subsequently discussed in an interdisciplinary molecular tumour board. Next-generation sequencing data were generated for 52 patients, with the full analysis possible in 46 of 52. Turnaround time from sample receipt until first report averaged 28 d. Twenty-six patients (50%) harbored a potentially druggable alteration with a prioritisation score of 'intermediate' or higher (level 4 of 7). Common targets included receptor tyrosine kinases, phosphoinositide 3-kinase-mammalian target of rapamycin pathway, mitogen-activated protein kinase pathway, and cell cycle control. Ten patients received a targeted therapy based on these findings, with responses observed in some previously treatment-refractory tumours. Comparative primary relapse analysis revealed substantial tumour evolution as well as one case of unsuspected secondary malignancy, highlighting the importance of re-biopsy at relapse. This study demonstrates the feasibility of comprehensive, real-time molecular profiling for high-risk paediatric cancer patients. This extended proof-of-concept, with examples of treatment consequences, expands upon previous personalised oncology endeavors, and presents a model with considerable interest and practical relevance in the burgeoning era of personalised medicine.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
Hyman, D. M., Puzanov, I., Subbiah, V., Faris, J. E., Chau, I., Blay, J.-Y., Wolf, J., Raje, N. S., Diamond, E. L., Hollebecque, A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1502309 · Cited by 1,764 · cited 1×
“Although not all tumours with a specific alteration will respond identically [38], this is still a more rational way to identify biomarkers of efficacy than the traditional ‘one-size-fits-all’.”
Germline Mutations in Predisposition Genes in Pediatric Cancer
Zhang, J., Walsh, M. F., Wu, G., Edmonson, M. N., Gruber, T. A., Easton, J., Hedges, D., Ma, X., Zhou, X., Yergeau, D. A., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1508054 · Cited by 1,345 · cited 3×
“Day 7-17 Median 11 days [7-19] Day 0-7 Median 4 days [1-27] Pediatric oncology center”
Le Tourneau, C., Delord, J.-P., Gonçalves, A., Gavoille, C., Dubot, C., Isambert, N., Campone, M., Trédan, O., Massiani, M.-A., Mauborgne, C., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00188-6 · Cited by 1,137
Childhood cancer survival in Europe 1999–2007: results of EUROCARE-5—a population-based study
Gatta, G., Botta, L., Rossi, S., Aareleid, T., Bielska-Lasota, M., Clavel, J., Dimitrova, N., Jakab, Z., Kaatsch, P., Lacour, B., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70548-5 · Cited by 1,075
Pharmacogenomics in the clinic
Relling, M. V., & Evans, W. E. (2015) · Nature · doi:10.1038/nature15817 · Cited by 904
Kempf-Bielack, B., Bielack, S. S., Jürgens, H., Branscheid, D., Berdel, W. E., Exner, G. U., Göbel, U., Helmke, K., Jundt, G., Kabisch, H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.063 · Cited by 643
Self-citationPersonalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study
Roychowdhury, S., Iyer, M. K., Robinson, D. R., Lonigro, R. J., Wu, Y.-M., Cao, X., Kalyana-Sundaram, S., Sam, L., Balbin, O. A., Quist, M. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3003161 · Cited by 628
deFuse: An Algorithm for Gene Fusion Discovery in Tumor RNA-Seq Data
McPherson, A., Hormozdiari, F., Zayed, A., Giuliany, R., Ha, G., Sun, M. G. F., Griffith, M., Heravi Moussavi, A., Senz, J., Melnyk, N., et al. (2011) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1001138 · Cited by 557
Oberlin, O., Rey, A., Lyden, E., Bisogno, G., Stevens, M. C. G., Meyer, W. H., Carli, M., & Anderson, J. R. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7207 · Cited by 484
Integrative Clinical Sequencing in the Management of Refractory or Relapsed Cancer in Youth
Mody, R. J., Wu, Y.-M., Lonigro, R. J., Cao, X., Roychowdhury, S., Vats, P., Frank, K. M., Prensner, J. R., Asangani, I., Palanisamy, N., et al. (2015) · JAMA · doi:10.1001/jama.2015.10080 · Cited by 411
Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis
Ramaswamy, V., Remke, M., Bouffet, E., Faria, C. C., Perreault, S., Cho, Y.-J., Shih, D. J., Luu, B., Dubuc, A. M., Northcott, P. A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70449-2 · Cited by 394
Self-citationDivergent clonal selection dominates medulloblastoma at recurrence
Morrissy, A. S., Garzia, L., Shih, D. J. H., Zuyderduyn, S., Huang, X., Skowron, P., Remke, M., Cavalli, F. M. G., Ramaswamy, V., Lindsay, P. E., et al. (2016) · Nature · doi:10.1038/nature16478 · Cited by 334
Self-citationLondon, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.3392 · Cited by 318
Risk of recurrence and survival after relapse in patients with Ewing sarcoma
Stahl, M., Ranft, A., Paulussen, M., Bölling, T., Vieth, V., Bielack, S., Görtitz, I., Braun‐Munzinger, G., Hardes, J., Jürgens, H., et al. (2011) · Pediatric Blood & Cancer · doi:10.1002/pbc.23040 · Cited by 315
Self-citationSpatiotemporal Evolution of the Primary Glioblastoma Genome
Kim, J., Lee, I.-H., Cho, H. J., Park, C.-K., Jung, Y.-S., Kim, Y., Nam, S. H., Kim, B. S., Johnson, M. D., Kong, D.-S., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.07.013 · Cited by 314
A comprehensive assessment of somatic mutation detection in cancer using whole-genome sequencing
Alioto, T. S., Buchhalter, I., Derdak, S., Hutter, B., Eldridge, M. D., Hovig, E., Heisler, L. E., Beck, T. A., Simpson, J. T., Tonon, L., et al. (2015) · Nature Communications · doi:10.1038/ncomms10001 · Cited by 306
Self-citationMutational dynamics between primary and relapse neuroblastomas
Schramm, A., Köster, J., Assenov, Y., Althoff, K., Peifer, M., Mahlow, E., Odersky, A., Beisser, D., Ernst, C., Henssen, A. G., et al. (2015) · Nature Genetics · doi:10.1038/ng.3349 · Cited by 304
Self-citationCin, H., Meyer, C., Herr, R., Janzarik, W. G., Lambert, S., Jones, D. T. W., Jacob, K., Benner, A., Witt, H., Remke, M., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0817-z · Cited by 234
Self-citationMAPK pathway activation in pilocytic astrocytoma
Jones, D. T. W., Gronych, J., Lichter, P., Witt, O., & Pfister, S. M. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0898-9 · Cited by 225
Self-citationTsimberidou, A.-M., Wen, S., Hong, D. S., Wheler, J. J., Falchook, G. S., Fu, S., Piha-Paul, S., Naing, A., Janku, F., Aldape, K., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0603 · Cited by 211
Meyer, U. A., Zanger, U. M., & Schwab, M. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100502 · Cited by 157
Self-citationTreatment of high-grade glioma in children and adolescents
MacDonald, T. J., Aguilera, D., & Kramm, C. M. (2011) · Neuro-Oncology · doi:10.1093/neuonc/nor092 · Cited by 154
Self-citationKobrinsky, N. L., Sposto, R., Shah, N. R., Anderson, J. R., DeLaat, C., Morse, M., Warkentin, P., Gilchrist, G. S., Cohen, M. D., Shina, D. C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.9.2390 · Cited by 117
Towards a European consensus for reporting incidental findings during clinical NGS testing
Hehir‐Kwa, J. Y., Claustres, M., Hastings, R. J., van Ravenswaaij‐Arts, C. M. A., Christenhusz, G. M., Genuardi, M., Melegh, B., Cambon‐Thomsen, A., Patsalis, P. C., Vermeesch, J. R., et al. (2015) · European Journal of Human Genetics · doi:10.1038/ejhg.2015.111 · Cited by 100
von Stackelberg, A., Völzke, E., Kühl, J., Seeger, K., Schrauder, A., Escherich, G., Henze, G., & Tallen, G. R. N. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.09.020 · Cited by 98
Tran, B., Brown, A. M. K., Bedard, P. L., Winquist, E., Goss, G. D., Hotte, S. J., Welch, S. A., Hirte, H. W., Zhang, T., Stein, L. D., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27817 · Cited by 83
Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors
Tóthová, Z., & Wagner, A. J. (2012) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328354c155 · Cited by 77
Molecular profiling of childhood cancer: Biomarkers and novel therapies
Saletta, F., Wadham, C., Ziegler, D. S., Marshall, G. M., Haber, M., McCowage, G. B., Norris, M. D., & Byrne, J. A. (2014) · BBA Clinical · doi:10.1016/j.bbacli.2014.06.003 · Cited by 47
Future of Clinical Genomics in Pediatric Oncology
Janeway, K. A., Place, A. E., Kieran, M. W., & Harris, M. H. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.8470 · Cited by 47
Patients in Pediatric Phase I and Early Phase II Clinical Oncology Trials at Gustave Roussy
Bautista, F. J., Giannatale, A. D., Dias, N., Fahd, M., Valteau‐Couanet, D., Couanet, D., Grill, J., Brugières, L., Dufour, C., Gaspar, N., et al. (2014) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0000000000000237 · Cited by 39
Translating genomic discoveries to the clinic in pediatric oncology
Bender, J. G., Verma, A. R., & Schiffman, J. D. (2014) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000172 · Cited by 33
Cited by
The landscape of genomic alterations across childhood cancers
ICGC PedBrain-Seq Project, Gröbner, S. N., ICGC MMML-Seq Project, Worst, B. C., Weischenfeldt, J., Buchhalter, I., Kleinheinz, K., Rudneva, V. A., Johann, P. D., Balasubramanian, G. P., et al. (2018) · Nature · doi:10.1038/nature25480 · Cited by 1,572
Self-citationGrünewald, T. G. P., Cidre-Aranaz, F., Surdez, D., Tomazou, E. M., de Álava, E., Kovar, H., Sorensen, P. H., Delattre, O., & Dirksen, U. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0003-x · Cited by 873
Self-citationReview of precision cancer medicine: Evolution of the treatment paradigm
Tsimberidou, A. M., Fountzilas, E., Nikanjam, M., & Kurzrock, R. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102019 · Cited by 756
Advances in the molecular genetics of gliomas — implications for classification and therapy
Reifenberger, G., Wirsching, H.-G., Knobbe-Thomsen, C. B., & Weller, M. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.204 · Cited by 662
Capper, D., Stichel, D., Sahm, F., Jones, D. T. W., Schrimpf, D., Sill, M., Schmid, S., Hovestadt, V., Reuss, D. E., Koelsche, C., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1879-y · Cited by 567
Self-citation
Metadata
- Authors
- Worst, B. C., van Tilburg, C. M., Balasubramanian, G. P., Fiesel, P., Witt, R., Freitag, A., Boudalil, M., Previti, C., Wolf, S., Schmidt, S., Chotewutmontri, S., Bewerunge-Hudler, M., Schick, M., Schlesner, M., Hutter, B., Taylor, L., Borst, T., Sutter, C., Bartram, C. R., Milde, T., Pfaff, E., Kulozik, A. E., von Stackelberg, A., Meisel, R., Borkhardt, A., Reinhardt, D., Klusmann, J.-H., Fleischhack, G., Tippelt, S., Dirksen, U., Jürgens, H., Kramm, C. M., von Bueren, A. O., Westermann, F., Fischer, M., Burkhardt, B., Wößmann, W., Nathrath, M., Bielack, S. S., Frühwald, M. C., Fulda, S., Klingebiel, T., Koscielniak, E., Schwab, M., Tremmel, R., Driever, P. H., Schulte, J. H., Brors, B., von Deimling, A., Lichter, P., Eggert, A., Capper, D., Pfister, S. M., Jones, D. T. W., & Witt, O.
- Venue
- European Journal of Cancer
- Publisher
- Elsevier BV
- Published
- 2016-09
- Volume
- 65
- Pages
- 91-101
- ISSN
- 0959-8049 (ISSN-L)
- OpenAlex
- W2503515884
- Cited by
- 330
- References
- 33
- FWCI
- 12.49
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.